Completed PHASE2/PHASE3 NCT00158574

Kilimanjaro IPTi Drug Options Trial

Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs

Sponsor: Kilimanjaro Christian Medical Centre, Tanzania

Conditions Malaria

Interventions Chlorproguanil dapsone Chlorproguanil-dapsone IPTi mefloquine Placebo Sulphadoxine-pryrimethamine mefloquine sulphadoxine-pyrimethamine

Updated 6 times since 2017 Last updated: Jan 11, 2017 Started: Jan 31, 2005 Primary completion: Apr 30, 2008 Completion: Jun 30, 2008

This PHASE2/PHASE3 trial investigates Malaria and is currently completed. Kilimanjaro Christian Medical Centre, Tanzania leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2_PHASE3

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kilimanjaro Christian Medical Centre, Tanzania
London School of Hygiene and Tropical Medicine
National Institute for Medical Research, Tanzania
University of Copenhagen

Data source: London School of Hygiene and Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tanga, Tanzania